Tower Research Capital LLC TRC Purchases 309 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Tower Research Capital LLC TRC grew its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6.3% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 5,178 shares of the medical equipment provider’s stock after buying an additional 309 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Lantheus were worth $463,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of LNTH. World Investment Advisors LLC bought a new stake in Lantheus during the 3rd quarter worth approximately $60,000. Wilmington Savings Fund Society FSB acquired a new position in Lantheus in the third quarter worth $25,000. Tidal Investments LLC grew its holdings in shares of Lantheus by 25.2% during the third quarter. Tidal Investments LLC now owns 17,621 shares of the medical equipment provider’s stock worth $1,934,000 after purchasing an additional 3,547 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Lantheus by 118.0% in the fourth quarter. GAMMA Investing LLC now owns 1,018 shares of the medical equipment provider’s stock valued at $91,000 after buying an additional 551 shares in the last quarter. Finally, Everence Capital Management Inc. bought a new position in shares of Lantheus in the fourth quarter valued at about $210,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Trading Up 1.2 %

NASDAQ LNTH opened at $103.96 on Wednesday. Lantheus Holdings, Inc. has a 12 month low of $65.89 and a 12 month high of $126.89. The stock has a 50-day simple moving average of $98.26 and a 200 day simple moving average of $95.14. The company has a market capitalization of $7.12 billion, a PE ratio of 17.30 and a beta of 0.20.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. As a group, sell-side analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on LNTH shares. Truist Financial raised their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. B. Riley lowered their price target on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a report on Friday, March 21st. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $129.43.

Insider Transactions at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 63,109 shares of company stock valued at $6,016,046 over the last three months. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.